Posttransplant lymphoproliferative disorder in pancreas transplantation: A single-center experience

Steven Paraskevas, James E. Coad, Angelika C Gruessner, Raja Kandaswamy, Abhinav Humar, David E R Sutherland, Rainer W G Gruessner

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background. Posttransplant lymphoproliferative disorder (PTLD) is a rare, serious complication of transplantation. The characteristics and associations of this disease in pancreas recipients have not been extensively studied. Methods. From January 1988 through December 2002, 787 pancreas and 569 kidney-pancreas transplants were performed at our institution. Eighteen pancreas recipients developed polymorphic PTLD or malignant lymphoma. Data on clinical course, organ involvement, molecular characteristics, and association with immunosuppression and recent cytomegalovirus (CMV) infection were compiled from the institutional transplant database. Patient survival was compared to recipients of liver and kidney transplants at the same center by using Kaplan-Meier analysis. Results. The 5-year cumulative incidence of PTLD in simultaneous pancreas-kidney, pancreas after kidney, and pancreas transplant alone recipients was 2.5%, 1.2%, and 1.0%, respectively (P = 0.23). A noticeably, but not significantly, higher cumulative incidence was seen in the more recent era since 1995 (2.1% vs. 0.9%, P = 0.15). PTLD in pancreas recipients carried a worse prognosis than in liver or kidney for recipients B-cell, early-onset, and Epstein Barr virus-positive lesions. PTLD was more aggressive in pancreas recipients, with a higher stage at presentation and a trend to more bone marrow involvement. There appeared to be a tendency toward association with recent CMV infection. Since 1995, PTLD recipients have had a lower exposure to antilymphocyte preparations (25 ± 5 vs. 10 ± 0.8) (P < 0.05). Conclusions. PTLD in pancreas recipients remains a rare but aggressive disease, and carries a worse prognosis in comparison to other transplant recipients. These heavily immunosuppressed patients, who often face multiple transplants, may be at greater risk; CMV infection may play an antecedent role.

Original languageEnglish (US)
Pages (from-to)613-622
Number of pages10
JournalTransplantation
Volume80
Issue number5
DOIs
StatePublished - Sep 15 2005
Externally publishedYes

Fingerprint

Pancreas Transplantation
Lymphoproliferative Disorders
Pancreas
Kidney
Cytomegalovirus Infections
Transplants
Liver
Incidence
Kaplan-Meier Estimate
Rare Diseases
Human Herpesvirus 4
Immunosuppression
Lymphoma
B-Lymphocytes
Transplantation
Bone Marrow
Databases

Keywords

  • Cytomegalovirus
  • Lymphoma
  • Outcomes
  • Pancreas

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Posttransplant lymphoproliferative disorder in pancreas transplantation : A single-center experience. / Paraskevas, Steven; Coad, James E.; Gruessner, Angelika C; Kandaswamy, Raja; Humar, Abhinav; Sutherland, David E R; Gruessner, Rainer W G.

In: Transplantation, Vol. 80, No. 5, 15.09.2005, p. 613-622.

Research output: Contribution to journalArticle

Paraskevas, Steven ; Coad, James E. ; Gruessner, Angelika C ; Kandaswamy, Raja ; Humar, Abhinav ; Sutherland, David E R ; Gruessner, Rainer W G. / Posttransplant lymphoproliferative disorder in pancreas transplantation : A single-center experience. In: Transplantation. 2005 ; Vol. 80, No. 5. pp. 613-622.
@article{f746622ba09448bbb1469190f297729f,
title = "Posttransplant lymphoproliferative disorder in pancreas transplantation: A single-center experience",
abstract = "Background. Posttransplant lymphoproliferative disorder (PTLD) is a rare, serious complication of transplantation. The characteristics and associations of this disease in pancreas recipients have not been extensively studied. Methods. From January 1988 through December 2002, 787 pancreas and 569 kidney-pancreas transplants were performed at our institution. Eighteen pancreas recipients developed polymorphic PTLD or malignant lymphoma. Data on clinical course, organ involvement, molecular characteristics, and association with immunosuppression and recent cytomegalovirus (CMV) infection were compiled from the institutional transplant database. Patient survival was compared to recipients of liver and kidney transplants at the same center by using Kaplan-Meier analysis. Results. The 5-year cumulative incidence of PTLD in simultaneous pancreas-kidney, pancreas after kidney, and pancreas transplant alone recipients was 2.5{\%}, 1.2{\%}, and 1.0{\%}, respectively (P = 0.23). A noticeably, but not significantly, higher cumulative incidence was seen in the more recent era since 1995 (2.1{\%} vs. 0.9{\%}, P = 0.15). PTLD in pancreas recipients carried a worse prognosis than in liver or kidney for recipients B-cell, early-onset, and Epstein Barr virus-positive lesions. PTLD was more aggressive in pancreas recipients, with a higher stage at presentation and a trend to more bone marrow involvement. There appeared to be a tendency toward association with recent CMV infection. Since 1995, PTLD recipients have had a lower exposure to antilymphocyte preparations (25 ± 5 vs. 10 ± 0.8) (P < 0.05). Conclusions. PTLD in pancreas recipients remains a rare but aggressive disease, and carries a worse prognosis in comparison to other transplant recipients. These heavily immunosuppressed patients, who often face multiple transplants, may be at greater risk; CMV infection may play an antecedent role.",
keywords = "Cytomegalovirus, Lymphoma, Outcomes, Pancreas",
author = "Steven Paraskevas and Coad, {James E.} and Gruessner, {Angelika C} and Raja Kandaswamy and Abhinav Humar and Sutherland, {David E R} and Gruessner, {Rainer W G}",
year = "2005",
month = "9",
day = "15",
doi = "10.1097/01.tp.0000168366.07896.d7",
language = "English (US)",
volume = "80",
pages = "613--622",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Posttransplant lymphoproliferative disorder in pancreas transplantation

T2 - A single-center experience

AU - Paraskevas, Steven

AU - Coad, James E.

AU - Gruessner, Angelika C

AU - Kandaswamy, Raja

AU - Humar, Abhinav

AU - Sutherland, David E R

AU - Gruessner, Rainer W G

PY - 2005/9/15

Y1 - 2005/9/15

N2 - Background. Posttransplant lymphoproliferative disorder (PTLD) is a rare, serious complication of transplantation. The characteristics and associations of this disease in pancreas recipients have not been extensively studied. Methods. From January 1988 through December 2002, 787 pancreas and 569 kidney-pancreas transplants were performed at our institution. Eighteen pancreas recipients developed polymorphic PTLD or malignant lymphoma. Data on clinical course, organ involvement, molecular characteristics, and association with immunosuppression and recent cytomegalovirus (CMV) infection were compiled from the institutional transplant database. Patient survival was compared to recipients of liver and kidney transplants at the same center by using Kaplan-Meier analysis. Results. The 5-year cumulative incidence of PTLD in simultaneous pancreas-kidney, pancreas after kidney, and pancreas transplant alone recipients was 2.5%, 1.2%, and 1.0%, respectively (P = 0.23). A noticeably, but not significantly, higher cumulative incidence was seen in the more recent era since 1995 (2.1% vs. 0.9%, P = 0.15). PTLD in pancreas recipients carried a worse prognosis than in liver or kidney for recipients B-cell, early-onset, and Epstein Barr virus-positive lesions. PTLD was more aggressive in pancreas recipients, with a higher stage at presentation and a trend to more bone marrow involvement. There appeared to be a tendency toward association with recent CMV infection. Since 1995, PTLD recipients have had a lower exposure to antilymphocyte preparations (25 ± 5 vs. 10 ± 0.8) (P < 0.05). Conclusions. PTLD in pancreas recipients remains a rare but aggressive disease, and carries a worse prognosis in comparison to other transplant recipients. These heavily immunosuppressed patients, who often face multiple transplants, may be at greater risk; CMV infection may play an antecedent role.

AB - Background. Posttransplant lymphoproliferative disorder (PTLD) is a rare, serious complication of transplantation. The characteristics and associations of this disease in pancreas recipients have not been extensively studied. Methods. From January 1988 through December 2002, 787 pancreas and 569 kidney-pancreas transplants were performed at our institution. Eighteen pancreas recipients developed polymorphic PTLD or malignant lymphoma. Data on clinical course, organ involvement, molecular characteristics, and association with immunosuppression and recent cytomegalovirus (CMV) infection were compiled from the institutional transplant database. Patient survival was compared to recipients of liver and kidney transplants at the same center by using Kaplan-Meier analysis. Results. The 5-year cumulative incidence of PTLD in simultaneous pancreas-kidney, pancreas after kidney, and pancreas transplant alone recipients was 2.5%, 1.2%, and 1.0%, respectively (P = 0.23). A noticeably, but not significantly, higher cumulative incidence was seen in the more recent era since 1995 (2.1% vs. 0.9%, P = 0.15). PTLD in pancreas recipients carried a worse prognosis than in liver or kidney for recipients B-cell, early-onset, and Epstein Barr virus-positive lesions. PTLD was more aggressive in pancreas recipients, with a higher stage at presentation and a trend to more bone marrow involvement. There appeared to be a tendency toward association with recent CMV infection. Since 1995, PTLD recipients have had a lower exposure to antilymphocyte preparations (25 ± 5 vs. 10 ± 0.8) (P < 0.05). Conclusions. PTLD in pancreas recipients remains a rare but aggressive disease, and carries a worse prognosis in comparison to other transplant recipients. These heavily immunosuppressed patients, who often face multiple transplants, may be at greater risk; CMV infection may play an antecedent role.

KW - Cytomegalovirus

KW - Lymphoma

KW - Outcomes

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=25444503010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444503010&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000168366.07896.d7

DO - 10.1097/01.tp.0000168366.07896.d7

M3 - Article

C2 - 16177635

AN - SCOPUS:25444503010

VL - 80

SP - 613

EP - 622

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 5

ER -